<?xml version="1.0" encoding="UTF-8"?>
<record
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xsi:schemaLocation="http://www.loc.gov/MARC21/slim http://www.loc.gov/standards/marcxml/schema/MARC21slim.xsd"
    xmlns="http://www.loc.gov/MARC21/slim">

  <leader>03620naa a22004697i 4500</leader>
  <controlfield tag="001">UMUN-OA-20261005-MLS-040</controlfield>
  <controlfield tag="003">local</controlfield>
  <controlfield tag="005">20261005174904.0</controlfield>
  <controlfield tag="006">m     o  d        </controlfield>
  <controlfield tag="007">cr||||||||||||</controlfield>
  <controlfield tag="008">261005s2023    xx      o    u000 0 eng d</controlfield>
  <datafield tag="024" ind1="7" ind2=" ">
    <subfield code="a">10.1038/s41392-023-01521-5</subfield>
    <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="035" ind1=" " ind2=" ">
    <subfield code="a">(local)EuropePMC:PMC10435569</subfield>
  </datafield>
  <datafield tag="040" ind1=" " ind2=" ">
    <subfield code="a">local</subfield>
    <subfield code="b">eng</subfield>
    <subfield code="c">local</subfield>
  </datafield>
  <datafield tag="041" ind1="0" ind2=" ">
    <subfield code="a">eng</subfield>
  </datafield>
  <datafield tag="100" ind1="0" ind2=" ">
    <subfield code="a">Lu Tang</subfield>
    <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="245" ind1="1" ind2="0">
    <subfield code="a">Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. /</subfield>
    <subfield code="c">Lu Tang; Zhongpei Huang; Heng Mei [and others].</subfield>
  </datafield>
  <datafield tag="264" ind1=" " ind2="1">
    <subfield code="a">[Place of publication not identified] :</subfield>
    <subfield code="b">Nature Publishing Group,</subfield>
    <subfield code="c">2023.</subfield>
  </datafield>
  <datafield tag="300" ind1=" " ind2=" ">
    <subfield code="a">1 online resource (1 article).</subfield>
  </datafield>
  <datafield tag="336" ind1=" " ind2=" ">
    <subfield code="a">text</subfield>
    <subfield code="b">txt</subfield>
    <subfield code="2">rdacontent</subfield>
  </datafield>
  <datafield tag="337" ind1=" " ind2=" ">
    <subfield code="a">computer</subfield>
    <subfield code="b">c</subfield>
    <subfield code="2">rdamedia</subfield>
  </datafield>
  <datafield tag="338" ind1=" " ind2=" ">
    <subfield code="a">online resource</subfield>
    <subfield code="b">cr</subfield>
    <subfield code="2">rdacarrier</subfield>
  </datafield>
  <datafield tag="500" ind1=" " ind2=" ">
    <subfield code="a">Publication type: Review article.</subfield>
  </datafield>
  <datafield tag="500" ind1=" " ind2=" ">
    <subfield code="a">Linked open-access copy: published version.</subfield>
  </datafield>
  <datafield tag="506" ind1="0" ind2=" ">
    <subfield code="a">Open access; no subscription required for the linked open-access version.</subfield>
    <subfield code="f">Unrestricted online access</subfield>
    <subfield code="2">star</subfield>
  </datafield>
  <datafield tag="520" ind1="3" ind2=" ">
    <subfield code="a">The immune-cell origin of hematologic malignancies provides a unique avenue for the understanding of both the mechanisms of immune responsiveness and immune escape, which has accelerated the progress of immunotherapy. Several categories of immunotherapies have been developed and are being further evaluated in clinical trials for the treatment of blood cancers, including stem cell transplantation, immune checkpoint inhibitors, antigen-targeted antibodies, antibody-drug conjugates, tumor vaccines, and adoptive cell therapies. These immunotherapies have shown the potential to induce long-term remission in refractory or relapsed patients and have led to a paradigm shift in cancer treatment with great clinical success. Different immunotherapeutic approaches have their advantages but also shortcomings that need to be addressed. To provide clinicians with timely information on these revolutionary therapeutic approaches, the comprehensive review provides historical perspectives on the applications and clinical considerations of the immunotherapy. Here, we first outline the recent advances that have been made in the understanding of the various categories of immunotherapies in the treatment of hematologic malignancies. We further discuss the specific mechanisms of action, summarize the clinical trials and outcomes of immunotherapies in hematologic malignancies, as well as the adverse effects and toxicity management and then provide novel insights into challenges and future directions.</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
    <subfield code="a">Creative Commons Attribution. See the linked licence for the applicable terms.</subfield>
    <subfield code="u">https://creativecommons.org/licenses/by/4.0/</subfield>
  </datafield>
  <datafield tag="546" ind1=" " ind2=" ">
    <subfield code="a">In English.</subfield>
  </datafield>
  <datafield tag="588" ind1="0" ind2=" ">
    <subfield code="a">Description generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source.</subfield>
  </datafield>
  <datafield tag="590" ind1=" " ind2=" ">
    <subfield code="a">Course allocation: B. Sc. Medical Laboratory Science.</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">B. Sc. Medical Laboratory Science</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">UMUN open access collection</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">hematology</subfield>
  </datafield>
  <datafield tag="655" ind1=" " ind2="4">
    <subfield code="a">Review articles.</subfield>
  </datafield>
  <datafield tag="700" ind1="0" ind2=" ">
    <subfield code="a">Zhongpei Huang</subfield>
    <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="700" ind1="0" ind2=" ">
    <subfield code="a">Heng Mei</subfield>
    <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="700" ind1="0" ind2=" ">
    <subfield code="a">Yu Hu</subfield>
    <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="773" ind1="0" ind2=" ">
    <subfield code="t">Signal transduction and targeted therapy</subfield>
    <subfield code="g">Vol. 8, no. 1, (2023), pages/article 306</subfield>
    <subfield code="x">2095-9907</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2="0">
    <subfield code="u">https://europepmc.org/articles/PMC10435569</subfield>
    <subfield code="y">Read open-access publication</subfield>
    <subfield code="z">Open access.</subfield>
    <subfield code="7">0</subfield>
  </datafield>
  <datafield tag="884" ind1=" " ind2=" ">
    <subfield code="a">Course selection and automated MARC21 enrichment from Europe PMC metadata.</subfield>
    <subfield code="g">20261005</subfield>
    <subfield code="k">https://europepmc.org/articles/PMC10435569</subfield>
    <subfield code="q">local</subfield>
  </datafield>
  <datafield tag="942" ind1=" " ind2=" ">
    <subfield code="n">0</subfield>
  </datafield>
  <datafield tag="999" ind1=" " ind2=" ">
    <subfield code="c">1182</subfield>
    <subfield code="d">1182</subfield>
  </datafield>
</record>
